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Tumor-derived molecular information and outcome
in hepatocellular carcinoma
To the Editor:
In the Journal Club section of the Journal, Wang and
Thorgeirsson [1] discussed our recent manuscript [2],
and provided a comprehensive overview and thoughtful
comments on the topic. However, their comment, ‘‘the
proﬁling of 6000 transcriptionally informative genes
could be the explanation why this report fails to identify
tumor-associated survival genes”, is misleading.
The informative gene panel was not deﬁned based on
abundance of transcripts, but on variation across sam-
ples, i.e., genes highly expressed in a subset of samples
but silenced in the rest were more likely to be chosen
as informative genes. In fact, most of the genes known
to be silenced due to epigenetic modiﬁcation in human
cancers, e.g., IGF2, CDKN2A (p16), CDH1 (E-cad-
herin), CDH13, APC, SOCS1, MGMT, and DAPK1,
are included in the panel (NCBI Gene Expression Omni-
bus platform Accession ID: GPL5474).
It is true that dysregulation of key molecular regula-
tors like p53 and MYC often cannot be captured by
transcripts of themselves. However, downstream eﬀect
of the dysregulation can be reproducibly captured in
transcriptome space as a ‘‘signature” [3,4]. As we
showed in the manuscript, the informative gene panel
was tailored for such ‘‘signature”-based transcriptome
analysis, and the majority of various published tumor-
derived signature genes are covered by the panel [2]. In
fact, the hepatocellular carcinoma (HCC) tumor-derived
survival predictive gene signature reported by Lee et al.
[5] was perfectly recapitulated using the panel [2]. These
clearly indicate that coverage in the panel is suﬃcient to
analyze tumor-derived molecular information. Further-
more, we could not ﬁnd any survival-correlated genes
in standard whole-genome gene-expression data gener-
ated on frozen HCC specimens (unpublished data).
Thus, we concluded that the lack of tumor-derived
survival-correlated gene is not due to the ‘‘informative
gene” proﬁling approach, but rather due to spectrum
of the type of recurrence in analyzed patient series.
The extent of association between tumor-derived infor-
mation and patient survival is unstable depending on
which of ‘‘early” or ‘‘late” recurrence is the major driver
of survival in each particular patient series analyzed in
each study (in other words, how eﬃciently tumor sur-
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In fact, Lee’s survival signature [5], developed in Chinese
patients whose outcome is assumedly driven by ‘‘early”
recurrence, had no obvious association with survival in
patient series collected from the US, Europe, and Japan,
in which ‘‘late” recurrence was the major driver of out-
come, although the signature was clearly reproduced in
all of these series [2].
There is no doubt tumor-derived molecular
information is important in terms of therapeutic target
discovery, and it is ideal to conﬁrm that it is associated
with patient outcome, i.e., ‘‘early” recurrence, at least in
the particular patient series in the study to rationalize
targeting the gene or pathway. However, the unstable
association could be a signiﬁcant limitation to utilize
the tumor-derived molecular information as a prognos-
tic marker, which should stably work across diverse pa-
tient populations across the world.
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Genome-based predictors for HCC outcomes: A matter of tumor
and/or stroma
To the Editor:
We appreciate the response by Yujin Hoshida [1]
regarding our interpretation [2] of his failure to iden-
tify tumor-associated survival genes when using the
informative gene panel approach described in his re-
cent study [3]. Hoshida argues that the informative
gene panel contains many genes reported to be
silenced in human tumors and thus insists that the
lack of tumor-derived survival genes in his recent
study is not due to the methodology used. Hoshida
concludes that the reason they are unable to identify
tumor-derived survival associated genes is due to the
type of recurrence they are studying. A majority of
cases in their cohorts have a late-recurrence, rather
than early-recurrence commonly found with cases
from most Asian cohorts. It is commonly believed
that late-recurrence is largely contributed by the devel-
opment of additional new tumor lesions due to high
carcinogenic activities in an at-risk liver while early-
recurrence is mainly attributed to metastatic disease.
His conclusion implies that no measurable molecular
change in the original HCC can be used to predict
the development of a new HCC, i.e., de novo HCC,
rather the ability to develop new HCC is only dictated
by the liver microenvironment. This is an interesting
idea but should be interpreted cautiously. We believe
such a conclusion is premature based on the current
body of evidence. Numerous tumor suppressor genes
and oncogenes have been identiﬁed to be responsible
for the development of HCC. For example, p53,
APC, beta-catenin and Myc, along with the transcripts
of their downstream targets, are frequently disregulat-
ed in HCC. The transcripts associated with these
molecular signaling pathways should be readily detect-
able in tumor cells. It is conceivable that some of
these transcripts could be predictive of the carcino-
genic activity common to HCC. While the informative
gene panel may contain many tumor suppressor genes,
many other important genes apparently are not in-
cluded. Because of the availability of the whole-gen-
ome DASL platform, such an uncertainty can now
be formally addressed. The mechanism for HCC
recurrence is currently unclear. Both early- and late-
recurrences can be independently attributed to meta-
